ArticleAJNR. American journal of neuroradiology2019
Perfusion MRI-Based Fractional Tumor Burden Differentiates between Tumor and Treatment Effect in Recurrent Glioblastomas and Informs Clinical Decision-Making.
Article in AJNR. American journal of neuroradiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 41 citations in OpenAlex.
- RCBVmax from DSC Perfusion MRI as a Supportive Imaging Biomarker for Differentiating IDH-Mutant Astrocytomas and Oligodendroglioma.Clinical neuroradiology · 2026Article
- Precision reirradiation in recurrent CNS tumors integrating biology techniques and multimodal care.Discover oncology · 2026Review
- Review
- Quantification of fractional tumor burden for the early detection of post-treatment glioblastoma progression.European radiology experimental · 2026Article
- Multisite Benchmark Study for Standardized Relative CBV in Untreated Brain Metastases Using the DSC-MRI Consensus Acquisition Protocol.AJNR. American journal of neuroradiology · 2025Article
- Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging.Cancers · 2025Review
- Identification of a Single-Dose, Low-Flip-Angle-Based CBV Threshold for Fractional Tumor Burden Mapping in Recurrent Glioblastoma.AJNR. American journal of neuroradiology · 2024Article
- How to evaluate perfusion imaging in post-treatment glioma: a comparison of three different analysis methods.Neuroradiology · 2024Article
- Arterial Spin-Labeling and DSC Perfusion Metrics Improve Agreement in Neuroradiologists' Clinical Interpretations of Posttreatment High-Grade Glioma Surveillance MR Imaging-An Institutional Experience.AJNR. American journal of neuroradiology · 2024Article
- Neuroimaging features of primary central nervous system post-transplantation lymphoproliferative disorder following hematopoietic stem cell transplant in patients with β-thalassemia: a case series and review of literature.Insights into imaging · 2024Article
- Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma.The neuroradiology journal · 2024Article
- Identification of single-dose, dual-echo based CBV threshold for fractional tumor burden mapping in recurrent glioblastoma.Frontiers in oncology · 2023Article
- Reproducibility of volume analysis of dynamic susceptibility contrast perfusion-weighted imaging in untreated glioblastomas.Neuroradiology · 2022Article
- Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.NMR in biomedicine · 2022Review
- DSC Perfusion MRI-Derived Fractional Tumor Burden and Relative CBV Differentiate Tumor Progression and Radiation Necrosis in Brain Metastases Treated with Stereotactic Radiosurgery.AJNR. American journal of neuroradiology · 2022Article
- MRI and PET of Brain Tumor Neuroinflammation in the Era of Immunotherapy, From theAJR. American journal of roentgenology · 2022Review
- Combined Diagnostic Accuracy of Diffusion and Perfusion MR Imaging to Differentiate Radiation-Induced Necrosis from Recurrence in Glioblastoma.Diagnostics (Basel, Switzerland) · 2022Article
- Review
- Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma.Frontiers in oncology · 2022Article
- Conventional and Advanced Imaging Techniques in Post-treatment Glioma Imaging.Frontiers in radiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeFractional tumor burden better correlates with histologic tumor volume fraction in treated glioblastoma than other perfusion metrics such as relative CBV. We defined fractional tumor burden classes with low and high blood volume to distinguish tumor from treatment effect and to determine whether fractional tumor burden can inform treatment-related decision-making. MATERIALS AND
methodsForty-seven patients with high-grade gliomas (primarily glioblastoma) with recurrent contrast-enhancing lesions on DSC-MR imaging were retrospectively evaluated after surgical sampling. Histopathologic examination defined treatment effect versus tumor. Normalized relative CBV thresholds of 1.0 and 1.75 were used to define low, intermediate, and high fractional tumor burden classes in each histopathologically defined group. Performance was assessed with an area under the receiver operating characteristic curve. Consensus agreement among physician raters reporting hypothetic changes in treatment-related decisions based on fractional tumor burden was compared with actual real-time treatment decisions.
resultsMean lower fractional tumor burden, high fractional tumor burden, and relative CBV of the contrast-enhancing volume were significantly different between treatment effect and tumor (
conclusionsHigh fractional tumor burden and low fractional tumor burden define fractions of the contrast-enhancing lesion volume with high and low blood volume, respectively, and can differentiate treatment effect from tumor in recurrent glioblastomas. Fractional tumor burden maps can also help to inform clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.